Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Duke Cancer Center

Neither a doctor nor a teaching hospital

Research payments

$5,897,093

1,216 payments

Through program year 2025, Duke Cancer Center is reported as receiving $5,897,093 in research payments, across 1,216 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,159,166 554
2024 Research $1,751,500 279
2023 Research $232,422 29
2022 Research $400,277 18
2021 Research $1,341,194 22
2020 Research $359,488 191
2019 Research $653,045 123

Breakdown

Who paid Research payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $2,335,127 182 payments
  2. Servier BioInnovation $1,535,422 35 payments
  3. Medivation Inc. $470,717 10 payments
  4. Amgen Inc. $449,371 4 payments
  5. Incyte Corporation $399,493 162 payments
  6. Karyopharm Therapeutics Inc. $264,387 66 payments
  7. Pfizer Inc. $175,750 8 payments
  8. Mirati Therapeutics, Inc. $87,353 1 payment
  9. AstraZeneca Pharmaceuticals LP $74,431 15 payments
  10. E.R. Squibb & Sons, L.L.C. $65,035 7 payments
Studies the money was for Research payments · program years 2019–2025
  1. Study of Vorasidenib, AG-881, in Participants With Residual Or Recurrent Grade 2 Glioma With An Idh1 Or Idh2 Mutation, Indigo $1,535,422 35 payments
  2. A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-na Metastatic Castration-Resistant Prostate Cancer mCRPC who have Progressed on a Next Generation Hormonal Agent NHA KEYNOTE-921 $780,402 9 payments
  3. Prosper A Multinational Phase 3 Randomized Doubleblind Placebocontrolled Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castrationresistant Prostate Cancer $470,717 10 payments
  4. Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-nave Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301) $419,512 1 payment
  5. A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab MK3475 with or without lenvatinib E7080,MK-7902 to evaluate the safety and efficacy of pembrolizumab and lenvatinib as 1L intervention in a PD-L1 selected population of participants with recurrent or metastatic head and neck squamous cell carcinoma R,M HNSCC LEAP-010 $288,287 8 payments
  6. A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent KEYNOTE-B21 , ENGOT-en11 , GOG-3053 $235,573 9 payments
  7. A Phase 1,2 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ARQ 531 in Selected Subjects with Relapsed or Refractory Hematologic Malignancies $195,576 2 payments
  8. An Openlabel Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and Mfolfox6 Versus Mfolfox6 Given With Or Without Either Cetuximab Or Bevacizumab As Firstline Treatment for Subjects With Her2 Metastatic Colorectal Cancer $175,750 8 payments
  9. A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib $147,573 3 payments
  10. A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy $121,047 11 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record